Dennis Sheehan, MD
Interventional Cardiology · Redwood City, CANPI 1205880101
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $899,280 of the $900,099 with a category attached, or 99.9%. Abbott accounts for 63.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $270,178, 3.3 times the $82,666 reported in 2019. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $10,228 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$567K
- Vital Connect, Inc$333K
- Novo Nordisk$579
- Sanofi-aventis U.S. LLC$108
- Portola Pharmaceuticals, LLC$74
- Brainscope Company, Inc.$58
Across 7 payments — averaging $41.19 each. An ownership or investment interest held by the physician or an immediate family member.
- Brainscope Company, Inc.$288
What the payments were for
- Consulting fees$899,280100%
- Food & beverage$8100%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 50 | $566,745 |
| Vital Connect, Inc | 27 | $332,535 |
| Novo Nordisk | 8 | $579 |
| Sanofi-aventis U.S. LLC | 1 | $108 |
| Portola Pharmaceuticals, LLC | 1 | $74 |
| Brainscope Company, Inc. | 1 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VITALPATCH RTM$241,349
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$17,850
- Wegovy$122
- Ozempic$122
- PRALUENT$108
How this compares
$900,099 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $173,334 |
| OzempicSemaglutide | 84 | $90,941 |
| EntrestoSacubitril/Valsartan | 74 | $78,428 |
| Repatha SureclickEvolocumab | 33 | $32,289 |
| JardianceEmpagliflozin | 25 | $28,316 |
| Praluent PenAlirocumab | 29 | $27,435 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $19,518 |
| Repatha SyringeEvolocumab | 19 | $19,288 |
| BrilintaTicagrelor | 17 | $19,173 |
| Ezetimibe | 451 | $17,265 |
| MounjaroTirzepatide | 16 | $17,104 |
| RybelsusSemaglutide | 11 | $16,906 |
| LivaloPitavastatin Calcium | 30 | $16,519 |
| LovazaOmega-3 Acid Ethyl Esters | 11 | $10,033 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $9,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $579 | $107,84895 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Redwood City
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
- Mitul PatelSan Diego$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.